NTLA
NASDAQ · Biotechnology
Intellia Therapeutics Inc
$13.71
-0.14 (-1.01%)
Open$13.78
Previous Close$13.85
Day High$14.07
Day Low$13.42
52W High$28.25
52W Low$6.83
Volume—
Avg Volume11.66M
Market Cap1.66B
P/E Ratio—
EPS$-3.83
SectorBiotechnology
Analyst Ratings
Buy
30 analysts
Price Target
+137.1% upside
Current
$13.71
$13.71
Target
$32.51
$32.51
$20.88
$32.51 avg
$45.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 75.53M | 69.24M | 223.20M |
| Net Income | -460,644,427 | -380,034,819 | -30,251,127 |
| Profit Margin | -609.9% | -579.4% | -13.6% |
| EBITDA | -481,329,878 | -419,161,595 | -52,265,042 |
| Free Cash Flow | — | — | -47,461,783 |
| Rev Growth | +9.1% | +9.1% | +19.1% |
| Debt/Equity | — | — | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |